2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 456

Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry
Abstract Number: 457

RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Abstract Number: 458

First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Abstract Number: 459

The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Abstract Number: 460

Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
Abstract Number: 461

Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
Abstract Number: 462

Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades
Abstract Number: 463

Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
Abstract Number: 464

Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Abstract Number: 465

MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Abstract Number: 466

Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
Abstract Number: 467

Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
Abstract Number: 468

Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria
Abstract Number: 469

Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
Abstract Number: 470

Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].